Results 31 to 40 of about 31,062 (287)

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. [PDF]

open access: yes, 2017
Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ( guided therapy ) with inconsistent ...
Adams, Kirkwood F.   +15 more
core   +3 more sources

Consequences of group III/IV afferent feedback and respiratory muscle work on exercise tolerance in heart failure with reduced ejection fraction

open access: yesExperimental Physiology, 2023
Exercise intolerance and exertional dyspnoea are the cardinal symptoms of heart failure with reduced ejection fraction (HFrEF). In HFrEF, abnormal autonomic and cardiopulmonary responses arising from locomotor muscle group III/IV afferent feedback is one
Joshua R. Smith   +3 more
doaj   +1 more source

Under pressure: pulmonary hypertension associated with left heart disease. [PDF]

open access: yes, 2015
© ERS 2015.Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood.
Farber, HW, Gibbs, S
core   +2 more sources

What can we learn from SOCRATES: more questions than answers? [PDF]

open access: yes, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Microvascular Disease with Heart Failure with Reduced and Preserved Ejection Fraction in Patients with Type 2 Diabetes [PDF]

open access: yes, 2020
Aims: Identification of patients with type 2 diabetes (T2D) at increased risk of incident heart failure (HF) beyond traditional risk factors such as prior myocardial infarction (MI) might allow selection of patients who would benefit from preventative ...
Doney, Alexander   +5 more
core   +2 more sources

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

open access: yes, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B   +22 more
core   +8 more sources

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis

open access: yesBrazilian Journal of Medical and Biological Research
Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have symptoms and signs of HF with normal or near-normal left ventricular ejection fraction (LVEF ≥50%).
Chao Ma   +4 more
doaj   +1 more source

Risk factors for new-onset heart failure with reduced or preserved ejection fraction in patients with ischemic heart disease: A cohort study

open access: yesJournal of Clinical Sciences, 2021
Background: Risk factors for heart failure (HF) with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF) in Ethiopian and Sub-Saharan African patients with ischemic heart disease (IHD) is not well-known.
Senbeta Guteta Abdissa
doaj   +1 more source

Neutrophils pro‐inflammatory and anti‐inflammatory cytokine release in patients with heart failure and reduced ejection fraction

open access: yesESC Heart Failure, 2021
Aims Heart failure with reduced ejection fraction (HFrEF) is characterized by sub‐clinical inflammation. Changes in selected biomarkers of inflammation concomitant with the release of pro‐inflammatory and anti‐inflammatory cytokines by neutrophils have ...
Diana Chaar   +6 more
doaj   +1 more source

The impact of peripheral arterial disease on patients with mechanical circulatory support. [PDF]

open access: yes, 2020
Background: Left ventricular assist devices (LVAD) are indicated as bridging or destination therapy for patients with advanced (Stage D) heart failure and reduced ejection fraction (HFrEF). Due to the clustering of the mutual risk factors, HFrEF patients
Ajmal, Rasikh   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy